Palisade Bio Valuation

PALI Stock  USD 1.61  0.12  8.05%   
Based on Macroaxis valuation methodology, the company appears to be undervalued. Palisade Bio holds a recent Real Value of $4.53 per share. The prevailing price of the company is $1.61. Our model determines the value of Palisade Bio from analyzing the company fundamentals such as Shares Outstanding of 149 M, return on equity of -2.29, and Shares Owned By Institutions of 45.92 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Palisade Bio's valuation include:
Price Book
69.4887
Enterprise Value
235.2 M
Enterprise Value Ebitda
0.5714
Price Sales
14.0311
Enterprise Value Revenue
234.8894
Undervalued
Today
1.61
Please note that Palisade Bio's price fluctuation is very risky at this time. Calculation of the real value of Palisade Bio is based on 3 months time horizon. Increasing Palisade Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Palisade Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Palisade Stock. However, Palisade Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.61 Real  4.53 Target  13.4 Hype  1.58 Naive  1.7
The intrinsic value of Palisade Bio's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Palisade Bio's stock price.
4.53
Real Value
11.68
Upside
Estimating the potential upside or downside of Palisade Bio helps investors to forecast how Palisade stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Palisade Bio more accurately as focusing exclusively on Palisade Bio's fundamentals will not take into account other important factors:
Earnings
Estimates
LowProjectedHigh
-0.37-0.13-0.04
Details
Hype
Prediction
LowEstimatedHigh
0.081.588.73
Details
Naive
Forecast
LowNext ValueHigh
0.031.708.85
Details
3 Analysts
Consensus
LowTarget PriceHigh
12.1913.4014.87
Details
When choosing an evaluation method for Palisade Bio, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.

Palisade Bio Cash

8.18 Million

Palisade Bio Total Value Analysis

Palisade Bio is at this time expected to have valuation of 235.2 M with market capitalization of 222.31 M, debt of 169 K, and cash on hands of 5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Palisade Bio fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
235.2 M
222.31 M
169 K
M

Palisade Bio Asset Utilization

One of the ways to look at asset utilization of Palisade is to check how much profit was generated for every dollar of assets it reports. Palisade Bio holds a negative application of assets of -0.88 pct., losing $0.008781 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Palisade Bio shows how discouraging it operates for each dollar spent on its assets.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Palisade Bio Profitability Analysis

Considering Palisade Bio's profitability and operating efficiency indicators, Palisade Bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Palisade Bio's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2006-06-30
Previous Quarter
-2.8 M
Current Value
-2.9 M
Quarterly Volatility
M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
The Palisade Bio's current Gross Profit is estimated to increase to -2,565. The current Pretax Profit Margin is estimated to decrease to -59.41
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin2.264.33
Way Down
Very volatile
For Palisade Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Palisade Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Palisade Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Palisade Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Palisade Bio over time as well as its relative position and ranking within its peers.

Palisade Bio Earnings per Share Projection vs Actual

By analyzing Palisade Bio's earnings estimates, investors can diagnose different trends across Palisade Bio's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Palisade Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Palisade Bio is projected to generate -0.1335 in earnings per share on the 31st of December 2025. Palisade Bio earnings estimates show analyst consensus about projected Palisade Bio EPS (Earning Per Share). It derives the highest and the lowest estimates based on Palisade Bio's historical volatility. Many public companies, such as Palisade Bio, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Palisade Bio Ownership Allocation

Palisade Bio owns a total of 149 Million outstanding shares. 30% of Palisade Bio outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Palisade Bio Profitability Analysis

Net Loss for the year was (14.44 M) with profit before overhead, payroll, taxes, and interest of 0.

About Palisade Bio Valuation

An absolute valuation paradigm, as applied to Palisade Stock, attempts to find the value of Palisade Bio based on its fundamental and basic technical indicators. By analyzing Palisade Bio's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Palisade Bio's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Palisade Bio. We calculate exposure to Palisade Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Palisade Bio's related companies.
Last ReportedProjected for Next Year
Gross Profit-2.7 K-2.6 K
Pretax Profit Margin(56.58)(59.41)
Operating Profit Margin(60.12)(63.13)
Net Loss(56.58)(59.41)
Gross Profit Margin 4.33  2.26 

Palisade Bio Current Valuation Indicators

Valuation refers to the process of determining the present value of Palisade Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Palisade we look at many different elements of the entity such as Palisade's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Palisade Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Palisade Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Palisade Bio's worth.

Complementary Tools for Palisade Stock analysis

When running Palisade Bio's price analysis, check to measure Palisade Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Palisade Bio is operating at the current time. Most of Palisade Bio's value examination focuses on studying past and present price action to predict the probability of Palisade Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Palisade Bio's price. Additionally, you may evaluate how the addition of Palisade Bio to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital